Microba Life Sciences (ASX:MAP) raises A$5m at a 20.6% discount with Sonic Healthcare backing the round, targeting CY2027 cashflow break-even.
Biotech Stocks
LTR Pharma (ASX:LTP) signs a binding US telehealth term sheet with Shed Holdings, locking in a 150,000-unit ROXUS minimum volume floor.
There are plenty of ASX Success Stories that can be categorised as such because they were bought out by a major player. Shareholders who rode things out over the journey will walk away satisfied without thought that they could be getting more. If the board (and perhaps a substantial shareholder or two) backs the bid,…
Island Pharmaceuticals (ASX:ILA) starts GMP manufacturing of Galidesivir with PI Health Sciences, the last big step before a pivotal Marburg FDA submission.
Opthea (ASX:OPT) returns to trading with A$31.2m, a LAM rare disease program and a proposed name change to Ceryvyn Therapeutics.
Imagion Biosystems (ASX:IBX) wins FDA IND clearance for MagSense HER2 Phase 1b/2 trial, with patient recruitment now targeted for Q3 2026.
Memphasys (ASX:MEM) lands another 1,000 Felix cartridge order from ITL as Qatar’s HMC adds a second console and UAE and Kuwait convert.
Noxopharm (ASX:NOX) reports 200-fold TLR8 amplification in human biopsies, backed by a US patent and Nature Immunology paper.
NeuroScientific (ASX:NSB) reported an 80% response rate in fistulising Crohn’s and is launching a second Phase 2 trial to fast-track Australian approval.
Aroa Biosurgery (ASX:ARX) printed NZ$12.6m EBITDA in FY26 then guided FY27 lower as it reinvests NZ$9m into Myriad and Symphony.
